Abstracts tagged "Adalimumab"

Abstract Number: 2466 • 2013 ACR/ARHP Annual Meeting
Long Term Efficacy Over Five Years Of Adalimumab In Patients With Active Non – Radiographic Axial Spondyloarthritis
Hildrun Haibel¹, Xenofon Baraliakos², Joachim Listing³, Juergen Braun⁴ and Joachim Sieper¹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Adalimumab had demonstrated good efficacy in 46 patients with active non-radiographic axial SpA in a 12-weeks, placebo-controlled trial with a 40-weeks, open-label extension.1,2In 19…
Abstract Number: 1058 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study
Hsin-Hua Chen^1,2, Der-Yuan Chen¹, Chao-Hsiung Tang³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Nicole Huang⁵, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²nstitute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan, ³Taipei Medical University, Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan
Background/Purpose: To evaluate possible interaction effect by concomitant methotrexate (MTX) use on the risk of drug discontinuation for adalimumab (ADA) compared with etanercept (ETN) in…
Abstract Number: 2360 • 2013 ACR/ARHP Annual Meeting
Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbA1c Over 1 Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis
Paola de Pablo¹, Fiona M. Maggs², David Carruthers³, Abdul A. Faizal⁴, Mark T. Pugh⁵ and Paresh Jobanputra⁶, ¹Rheumatology, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, University of Birmingham, College of Medical & Dental Sciences, Queen Elizabeth Hospital Birmingham, UK, Birmingham, United Kingdom, ²Department of Rheumatology, Queen Elizabeth Hospital Birmingham, UK, Birmingham, United Kingdom, ³Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, UK, Birmingham, United Kingdom, ⁴Department of Rheumatology, Solihull Hospital, Heart of England NHS Foundation Trust, UK, Solihull, United Kingdom, ⁵Department of Rheumatology, Saint Mary's Hospital, UK, Isle of Wight, United Kingdom, ⁶Department of Rheumatology, Queen Elizabeth Hospital Birmingham, UK., Birmingham, United Kingdom
Background/Purpose: Inflammation such as that which occurs in rheumatoid arthritis (RA) is associated with insulin resistance and risk of diabetes mellitus (DM). Some DMARDs including…
Abstract Number: 875 • 2013 ACR/ARHP Annual Meeting
Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial
Sophine B. Krintel¹, Christian Dehlendorff², Merete Lund Hetland³, Kim Hørslev-Petersen⁴, Klaus K. Andersen², Peter Junker⁵, Jan Pødenphant⁶, Torkell Ellingsen⁷, Palle Ahlqvist⁸, Hanne M. Lindegaard⁹, Asta Linauskas¹⁰, Annette Schlemmer¹¹, Mette Y. Dam¹², Ib Hansen¹³, Hans Chr Horn¹⁴, Anette Jørgensen¹⁵, Johnny Raun¹⁶, Christian G. Ammitzbøll¹², Mikkel Østergaard¹⁷, Kristian Stengaard-Pedersen¹² and Julia S. Johansen¹⁸, ¹Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ²Danish Cancer Society Research Center, Copenhagen, Denmark, ³DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ⁴Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ⁵University of Southern Denmark, Odense, Denmark, ⁶Copenhagen University at Gentofte, Hellerup, Denmark, ⁷Silkeborg Regional Hospital, Silkeborg, Denmark, ⁸University of Southern Denmark, Vejle, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁰Vendsyssel Hospital, Hjørring, Denmark, ¹¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹²Arhus University Hospital, Aarhus, Denmark, ¹³Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹⁴Internal Medicine/Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁵Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹⁶University of Southern Denmark, Graasten, Denmark, ¹⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ¹⁸Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark
Background/Purpose: The response to anti-TNF therapy varies widely between patients with rheumatoid arthritis (RA). MicroRNAs (miRNAs) are suggested to influence susceptibility to RA and disease…
Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…
Abstract Number: 793 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Gerd Horneff³, Aileen L. Pangan⁴, Kristina Unnebrink⁵ and Jaclyn K. Anderson⁴, ¹Rheumatology, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²Pediatric Rheumatology, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the…
Abstract Number: 2366 • 2013 ACR/ARHP Annual Meeting
Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 24 Weeks Data From The Anouveau Study
Yoshiya Tanaka¹, Yasuhiko Shinmura², Ryo Nakajima², Takahiro Muramatsu², Shuichi Komatsu³, Tadamichi Kubo², Aki Kuroki⁴, Ataru Igarashi⁵, Toshiro Tango⁶ and Tsutomu Takeuchi⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ³Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, ⁴Medical Affairs, AbbVie GK, Tokyo, Japan, ⁵Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, ⁶Center for Medical Statistics, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) incur higher costs owing to missed work days and short-time disability. Although methotrexate combined with adalimumab (ADA) provides comprehensive…
Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Kirsten Minden¹, Klaus Tenbrock², Gerd Horneff³ and Hans-Iko Huppertz⁴, ¹Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ²University Aachen, Aachen, Germany, ³Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Prof. Hess Childrens Hospital, Bremen, Germany
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Josef S. Smolen¹, Ronald F. van Vollenhoven², Roy Fleischmann³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Anabela Cardoso⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Leeds Teaching Hospital, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie, Amadora, Portugal, ⁸AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁹University of California, San Diego, La Jolla, CA
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
Abstract Number: 483 • 2013 ACR/ARHP Annual Meeting
Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study
Sandra L Goss¹, Cheri E Klein¹, Hartmut Kupper², Gerd Burmester³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ³Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Higher exposure and lower immunogenicity rates have been observed for adalimumab when co-administered with methotrexate (MTX) compared to adalimumab monotherapy. The CONCERTO study was…
Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
Sarah Thomas¹, Nabeel Borazan², Lewei Duan³, Nashla Barroso⁴, Sara Taroumian⁵, Banjamin Kretzmann⁶, Ricardo Bardales⁶ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, Rheumatology UCLA, Los Angeles, CA, ³David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁵Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ⁶Rheumatology, University of California Los Angeles, los angeles, CA

AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
Abstract Number: 488 • 2013 ACR/ARHP Annual Meeting
The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration
Walid Awni¹, Sabine Pilari², Ghada Ahmed³ and Peter Noertersheuser², ¹AbbVie Inc., North Chicago, IL, ²AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ³AbbVie, North Chicago, IL
Background/Purpose: Co-administration of methotrexate (MTX) has a significant effect on the pharmacokinetics (PK) of adalimumab (ADAL). MTX may impact the PK of other drugs by…
Abstract Number: 1866 • 2013 ACR/ARHP Annual Meeting
Primary Human Cell BioMAP^® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures
Seng-Lai Tan¹, Alison O'Mahony², Ellen L. Berg², Kandeepan Ganeshalingam³ and Ernest H. Choy⁴, ¹Inflammation, Hoffmann-La Roche, Nutley, NJ, ²BioSeek, South San Francisco, CA, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Proinflammatory cytokines cause joint inflammation and destruction in patients with rheumatoid arthritis, as exemplified by the therapeutic success of inhibiting tumor necrosis factor alpha…
Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Ying-Ming Chiu¹, Chao-Hsiung Tang², Sheng-Tzu Hung³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Hsiao-Yi Lin⁵, ¹Changhua Christian Hospital, Changhua City, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Formosa Biomedical Technology Corp., Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Immunology and Rheumatology, Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…
Abstract Number: 1826 • 2013 ACR/ARHP Annual Meeting
Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding
Bohdan P. Harvey and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].